** Analysts at Morningstar raise fair value estimate on Australia's Polynovo Ltd PNV.AX by 5% to A$1.15
** Medical devices maker Polynovo, on Tuesday, recorded its highest ever monthly sales of A$10.1 mln ($6.3 mln) in November
** Company logged total group revenue of A$49.6 mln till November, up 25.5% vs the same period last year
** Fiscal 2025 revenue forecast of A$136 mln ($84.95 mln) implies 32% growth on last year as we anticipate a stronger-second half on favourable currency movements and continued market share gains - Morningstar
** Six of eight analysts rate the stock "buy" or higher, two "hold"; their median PT is A$2.77, according to data compiled by LSEG
** PNV stock down 24.5% YTD, as of the last close
($1 = 1.6010 Australian dollars)
(Reporting by Roshan Thomas in Bengaluru)
((Roshan.Thomas@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.